Phenylketonuria Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Route of Administration (Oral, Parenteral), by Product (Dietary Supplement, Drugs), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Pediatric Clinics), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 502.18 million

CAGR (2023-2028)

11.00%

Fastest Growing Segment

Online Pharmacies

Largest Market

North America

 

Market Overview

Global Phenylketonuria Treatment Market has valued at USD 502.18 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 11.00% through 2028.   Phenylketonuria (PKU) is a rare genetic disorder that affects an individual's ability to metabolize phenylalanine, an essential amino acid found in protein-containing foods. PKU is an autosomal recessive disorder, meaning it occurs when a person inherits two mutated copies of the PAH gene (phenylalanine hydroxylase gene), one from each parent. The PAH gene provides instructions for making an enzyme called phenylalanine hydroxylase, which is responsible for breaking down phenylalanine in the body. In people with PKU, there is a deficiency or complete absence of phenylalanine hydroxylase enzyme activity due to mutations in the PAH gene. As a result, phenylalanine cannot be effectively converted into tyrosine. The inability to metabolize phenylalanine leads to its accumulation in the bloodstream, resulting in elevated blood phenylalanine levels. High levels of phenylalanine are toxic to the central nervous system. Excess phenylalanine can damage the developing brain, particularly in infants and young children. It can lead to intellectual and developmental disabilities, behavioral problems, seizures, and other neurological complications if left untreated.

An increasing awareness of PKU and improved diagnostic capabilities have led to more individuals being diagnosed with PKU. This higher prevalence drives the demand for PKU treatments. Ongoing research and development efforts have led to advancements in PKU treatment options, including new medical foods, dietary supplements, and enzyme replacement therapies (ERTs). These innovations provide more choices for patients and healthcare providers. Research into gene therapies for PKU was gaining momentum. Gene editing technologies like CRISPR-Cas9 held the promise of potentially curing the underlying genetic cause of PKU, which could revolutionize treatment. Patient advocacy groups and healthcare organizations have been actively raising awareness about PKU and related metabolic disorders. This increased awareness encourages early diagnosis and treatment. Patient advocacy groups play a significant role in driving research, raising funds, and advocating for improved access to treatments. Their efforts influence policy changes and promote investment in PKU research. Technological advancements in healthcare, such as telehealth and remote monitoring, have improved access to care for PKU patients and facilitated ongoing management.

Key Market Drivers

Increasing Gene Therapy Research

Gene therapy research has the potential to significantly impact the treatment landscape for Phenylketonuria (PKU) and drive the demand for new and innovative PKU treatments. PKU is a genetic disorder caused by mutations in the PAH gene, which results in the inability to properly metabolize phenylalanine, an amino acid found in protein-containing foods. Gene therapy research for PKU aims to address the root cause of the condition by correcting or compensating for the genetic mutation responsible for the disease. Gene therapy research offers the promise of a potential cure for PKU by addressing the genetic defect responsible for the condition. If successful, gene therapy could eliminate the need for lifelong dietary restrictions and medical foods, which are currently the standard of care. Successful gene therapy could significantly improve the quality of life for individuals with PKU by allowing them to consume a more normal diet without worrying about phenylalanine restrictions. This improvement in quality of life would drive demand for gene therapies among PKU patients and their families.

PKU treatment is currently burdensome, involving strict dietary management, frequent monitoring, and the consumption of specialized medical foods. Gene therapy has the potential to reduce or eliminate many of these treatment-related challenges, making it an attractive option for patients. While current treatments are effective for many PKU patients, they are not suitable for everyone. Gene therapy could expand treatment options to a broader range of individuals, including those who do not respond well to existing treatments or who find them difficult to adhere to. As awareness of gene therapy research for PKU grows, patients and their families may actively seek out these treatments, leading to increased demand for clinical trials and approved therapies. The promise of gene therapy has attracted investment and innovation from biotechnology and pharmaceutical companies. Increased research and development in this area can lead to breakthroughs and advancements in the field. Ongoing clinical trials for gene therapy in PKU create opportunities for patients to access experimental treatments, further driving interest and demand in the patient community. This factor will help in the development of the Global Phenylketonuria Treatment Market.

Rising PKU Prevalence

Advances in medical technology and genetic testing have made it easier to diagnose PKU accurately. Earlier and more precise diagnoses have led to an increase in the number of individuals identified with the condition. Many countries have expanded their newborn screening programs to include PKU testing. This allows for the early identification of affected infants, even before symptoms become apparent. Increased awareness among healthcare professionals, parents, and the public has led to more individuals seeking medical advice and genetic testing when symptoms or risk factors are present. As the global population continues to grow, the absolute number of individuals born with rare genetic disorders like PKU also increases. In some populations, consanguineous (close-relative) marriages can increase the likelihood of autosomal recessive genetic disorders like PKU. In such cases, a child has a higher risk of inheriting two copies of the mutated gene, leading to the disorder. Demographic shifts, such as immigration and increased genetic diversity, can affect the prevalence of PKU in different regions. Some environmental factors, such as exposure to certain toxins or chemicals, may play a role in the development of PKU-like symptoms in individuals without the genetic mutation. These cases may contribute to the perception of increased prevalence. While the rising prevalence of PKU highlights the importance of early diagnosis and treatment, it also underscores the need for increased healthcare resources and support for affected individuals and their families. Access to specialized clinics, medical foods, dietary guidance, and psychological support is crucial in managing PKU and improving the quality of life for those affected by the condition. This factor will pace up the demand of the Global Phenylketonuria Treatment Market.

Technological Advancements

Technological advances in newborn screening methods have made it possible to identify PKU early in life. The introduction of tandem mass spectrometry (MS/MS) has greatly improved the accuracy and efficiency of newborn PKU screening, allowing for earlier diagnosis and treatment initiation. Telehealth platforms and digital health technologies have become increasingly valuable for PKU patients. These tools enable remote consultations with healthcare providers, facilitate monitoring of dietary adherence and blood phenylalanine levels, and offer educational resources for patients and caregivers. Mobile apps designed for PKU management have become popular. These apps can help patients track their dietary intake, record blood phenylalanine levels, set reminders for medication, and access educational materials, making self-management more convenient. Advances in genetic testing technologies have made it easier to identify specific PKU mutations in individuals. This information can help tailor treatment plans to each patient's unique genetic profile, optimizing care. Technological innovation has led to the development of pharmacological therapies like sapropterin (Kuvan). This medication, used in combination with dietary management, can help some PKU patients by increasing their tolerance for phenylalanine. While still in the experimental stages, gene therapy research holds great promise for PKU treatment. Gene editing technologies like CRISPR-Cas9 are being explored to correct the underlying genetic mutation responsible for PKU.

Specialized nutritional tracking software and devices can help individuals with PKU monitor their daily protein intake, track phenylalanine levels, and make informed dietary choices. AI algorithms are being developed to assist in predicting how specific dietary choices may impact blood phenylalanine levels in PKU patients. This can aid in personalized dietary planning. Technological advancements in food science and nutrition have led to the development of better-tasting, more palatable, and nutritionally balanced low-protein foods and medical foods for PKU patients. EHR systems help healthcare providers manage PKU patient data efficiently, track treatment progress, and ensure continuity of care. They also facilitate communication among healthcare professionals involved in a patient's treatment. Advances in biotechnology have allowed for the development of enzyme replacement therapies (ERTs) for PKU. These therapies involve the use of genetically engineered enzymes to help metabolize phenylalanine. Online communities and social media platforms provide PKU patients and their families with a means to connect, share experiences, and access support, information, and resources. This factor will accelerate the demand of the Global Phenylketonuria Treatment Market.


                                                                                    Download Free Sample Report

Key Market Challenges

Limited Treatment Options

The primary treatment for PKU involves adhering to a strict low-phenylalanine diet. This can be challenging for patients as it restricts the consumption of common protein-containing foods like meat, dairy, and grains. The limited dietary choices can lead to feelings of social isolation and dietary monotony. Many PKU patients rely on specialized medical foods that provide essential nutrients while minimizing phenylalanine intake. However, the options for medical foods have historically been limited, and the taste and texture of these products have not always been palatable, leading to compliance issues. Until recently, there were limited targeted therapies for PKU. Traditional treatment options focused on dietary management, and some patients found it difficult to achieve and maintain appropriate phenylalanine levels through diet alone. While pharmacological options like sapropterin (Kuvan) are available to some PKU patients, they do not work for everyone. The effectiveness of these medications can vary, and they are often used in combination with dietary restrictions. Access to PKU treatments can vary by region, and not all patients have easy access to specialized clinics, medical foods, or medications. Limited access can be a significant challenge, especially in rural or underserved areas. Historically, PKU has not received as much research and development attention as more common diseases. Limited investment in research can result in a lack of innovative treatment options. PKU is a heterogeneous condition, meaning that individuals may respond differently to treatments. What works for one patient may not be effective for another, underscoring the need for a variety of treatment options.

Psychosocial and Quality of Life Issues

PKU patients must adhere to a strict low-phenylalanine diet throughout their lives. This dietary restriction can be burdensome and isolating, as it limits their food choices and makes it challenging to enjoy typical meals with family and friends. PKU patients may experience social isolation due to their dietary restrictions. They often need to bring their own specially formulated low-protein foods to social gatherings and events, which can lead to feelings of exclusion. The lifelong nature of PKU and the need for strict dietary management can contribute to anxiety, depression, and stress. Patients may experience frustration, body image issues, and concerns about their condition's impact on their future. Children with PKU may face difficulties at school due to dietary restrictions and the need for special accommodation. They may require additional support to manage their condition while pursuing their education. The limited variety of low-protein foods available for PKU patients can lead to monotony in their diet, affecting their enjoyment of meals and overall quality of life. Strict adherence to PKU treatment is essential for maintaining healthy phenylalanine levels. Patients must consistently monitor their dietary intake and adhere to prescribed medical foods and medications, which can be challenging. Many PKU patients require psychological support and counseling to cope with the emotional and social challenges associated with their condition. Transitioning from pediatric to adult care can be particularly challenging for PKU patients. They may struggle to manage their condition independently and may require guidance in making lifestyle adjustments. The cost of medical foods, dietary supplements, and specialized care can be a financial burden for PKU patients and their families, potentially impacting their quality of life. Access to specialized PKU clinics and healthcare providers can be limited in some regions, affecting the quality of care and support available to patients.

Key Market Trends

Nutraceuticals and Supplements

 Nutraceuticals and supplements designed for PKU patients often serve as protein substitutes. These products provide essential amino acids, vitamins, and minerals, allowing patients to meet their nutritional requirements without consuming phenylalanine-containing foods. Specialized amino acid formulations are available in supplement form for PKU patients. These products are carefully balanced to provide the necessary amino acids while keeping phenylalanine levels low. PKU patients may require additional vitamins and minerals due to dietary restrictions. Nutraceuticals and supplements are designed to address potential nutrient deficiencies associated with PKU. Some nutraceuticals are formulated to be low in phenylalanine, making them suitable for PKU patients. These products can include low-protein bread, pasta, and other foods that can help diversify the diet. Nutraceuticals are often categorized as medical foods and are available by prescription. These products are specially formulated to provide adequate nutrition while minimizing phenylalanine intake. Advances in nutraceuticals and supplements allow for more personalized nutrition plans tailored to an individual's age, nutritional needs, and PKU severity. Efforts have been made to improve the taste and palatability of nutraceuticals and supplements for PKU patients, making them more appealing and easier to incorporate into the diet. Nutraceuticals and supplements offer convenience to PKU patients and their caregivers. They can be easily integrated into daily dietary routines, allowing for greater flexibility and adherence to treatment plans. Many countries have regulations in place to ensure the safety and quality of nutraceuticals and medical foods for PKU. Regulatory oversight helps maintain the integrity of these products.

Segmental Insights

Route of Administration Insights

In 2022, the Global Phenylketonuria Treatment Market largest share was held by Oral route of administration segment and is predicted to continue expanding over the coming years. The oral route of administration is often the most convenient for patients, especially in the case of chronic conditions like PKU. Many PKU medications and supplements are available in oral forms such as tablets, capsules, or liquids, which are easy for patients to take at home or while on the go. PKU treatment typically involves taking multiple doses of medication or supplements daily to manage phenylalanine levels. Oral administration makes it easier for patients to adhere to their treatment regimen, as it does not require medical procedures or injections. The market for oral PKU treatments offers a variety of products, including enzyme replacement therapies (ERTs), amino acid formulations, and dietary supplements, which can be taken orally. This variety allows healthcare professionals to tailor treatment plans to individual patient needs. Oral administration is non-invasive, making it preferable for patients who may be averse to injections or other invasive forms of treatment. It reduces the discomfort and anxiety associated with medical procedures.

Product Insights

In 2022, the Global Phenylketonuria Treatment Market largest share was held by Dietary Supplement segment and is predicted to continue expanding over the coming years.  Dietary management is a fundamental aspect of treating PKU. Individuals with PKU need to follow a lifelong low-protein diet that restricts their intake of phenylalanine. Dietary supplements play a crucial role in helping patients meet their nutritional needs while adhering to this restricted diet. PKU diets can be deficient in certain nutrients, such as essential amino acids, vitamins, and minerals, due to the limited intake of protein-containing foods. Dietary supplements are designed to provide these essential nutrients, ensuring that patients receive a balanced diet despite their dietary restrictions. Dietary supplements come in various forms, including capsules, tablets, powders, and liquids, making them convenient for patients to incorporate into their daily routines. They can be taken alongside regular meals, providing an extra level of convenience. The dietary supplement market offers a wide range of products tailored to the specific needs of PKU patients. These supplements can address nutritional gaps and may include amino acid formulations, vitamins, minerals, and other essential nutrients.

Distribution Channel Insights

In 2022, the Global Phenylketonuria Treatment Market largest share was held by Online Pharmacies segment in the forecast period and is predicted to continue expanding over the coming years.  Online pharmacies offer convenience to patients and caregivers who need PKU treatments. They provide the option to purchase necessary medications and medical foods from the comfort of one's home, reducing the need for physical visits to brick-and-mortar pharmacies or clinics. Online pharmacies often have a broader range of PKU-related products, including specialized low-protein medical foods, dietary supplements, and prescription medications. This variety allows patients to find the specific products that meet their needs. PKU is a rare genetic disorder, and some individuals may prefer the privacy that online pharmacies offer when ordering and receiving treatments. Online platforms allow for discreet and confidential transactions. Online pharmacies enable patients and caregivers to compare prices easily and potentially find cost-effective options for PKU treatments. This transparency can be particularly important, as some PKU treatments can be expensive.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Phenylketonuria Treatment Market in 2022. North America, particularly the United States and Canada, had relatively high levels of awareness about rare genetic disorders like PKU. This led to early diagnosis and intervention, increasing the demand for PKU treatments. The region had a well-developed healthcare infrastructure, including specialized clinics and centers focused on metabolic disorders. This infrastructure supported the diagnosis and treatment of PKU. Many pharmaceutical and biotechnology companies based in North America were actively involved in research and development efforts related to PKU treatments. These companies conducted clinical trials, developed new therapies, and produced medical foods and supplements for PKU patients. Regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, provided a framework for approving and regulating PKU treatments. This encouraged innovation and investment in the field.

Recent Developments

  • In May 2020, PTC Therapeutics, Inc. announced that it has reached a deal to buy Censa Pharmaceuticals, Inc., a biopharmaceutical company specialising in the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other conditions linked to defects in the tetrahydrobiopterin (BH4) biochemical pathways that can be identified at birth. The boards of both corporations gave their approval to the deal. CNSA-001 has being investigated as a potential therapy for rare metabolic disorders linked to flaws in the biochemical processes that produce tetrahydrobiopterin. As a precursor to intracellular tetrahydrobiopterin, which is a vital enzyme cofactor involved in the metabolism and synthesis of various metabolic products, sepiapterin, a synthetic substance, is used in CNSA-001, an oral formulation. The main and secondary objectives of the Phase 2 study testing CNSA-001 for PKU were reached in December 20191, and the programme is now ready for Phase 3.
  • In May 2018, the phenylketonuria (PKU) hereditary disorder, which is rare and dangerous, has been given Palynziq's approval for adult patients. Phenylalanine (Phe), an amino acid found in meals containing protein and high-intensity sweeteners utilised in a range of foods and beverages, cannot be broken down in patients with PKU. For adult PKU patients with uncontrolled blood Phe concentrations despite receiving medication, Palynziq is a new enzyme therapy.

Key Market Players

  • BioMarin Pharmaceutical Inc.
  • Synlogic, Inc.
  • Retrophin, Inc.
  • Daiichi Sankyo Company, Limited
  • Codexis, Inc.
  • SOM Innovation Biotech SL
  • Homology Medicines, Inc.

By Route of Administration

By Product

By Distribution Channel

By Region

·         Oral

·        Parenteral

·         Dietary Supplement

·         Drugs

·         Hospital Pharmacies

·         Online Pharmacies

·         Pediatric Clinics

·         North America

·         Asia-Pacific

·         Europe

·         South America

·         Middle East & Africa

Report Scope:

In this report, the Global Phenylketonuria Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •     Phenylketonuria Treatment Market, By Route of Administration:

o   Oral

o   Parenteral

·           Phenylketonuria Treatment Market, By Product:

o   Dietary Supplement

o   Drugs

§  Biopten

§  Kuvan

  •     Phenylketonuria Treatment Market, By Distribution Channel:

o   Hospital Pharmacies

o   Online Pharmacies

o   Pediatric Clinics

  • Global Phenylketonuria Treatment Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Phenylketonuria Treatment Market.

Available Customizations:

Global Phenylketonuria Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Phenylketonuria Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Phenylketonuria Treatment Market Outlook

5.1.  Market Size & Forecast

5.1.1.        By Value

5.2.  Market Share & Forecast

5.2.1.        By Route of Administration (Oral, Parenteral)

5.2.2.        By Product (Dietary Supplement, Drugs)

5.2.3.        By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Pediatric Clinics)

5.2.4.        By Company (2022)

5.3.  Market Map

6.    Asia Pacific Phenylketonuria Treatment Market Outlook

6.1.  Market Size & Forecast

6.1.1.        By Value

6.2.  Market Share & Forecast

6.2.1.        By Route of Administration

6.2.2.        By Product

6.2.3.        By Distribution Channel

6.2.4.        By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.        China Phenylketonuria Treatment Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Route of Administration

6.3.1.2.2.           By Product

6.3.1.2.3.           By Distribution Channel

6.3.2.        India Phenylketonuria Treatment Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Route of Administration

6.3.2.2.2.           By Product

6.3.2.2.3.           By Distribution Channel

6.3.3.        Australia Phenylketonuria Treatment Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Route of Administration

6.3.3.2.2.           By Product

6.3.3.2.3.           By Distribution Channel

6.3.4.        Japan Phenylketonuria Treatment Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Route of Administration

6.3.4.2.2.           By Product

6.3.4.2.3.           By Distribution Channel

6.3.5.        South Korea Phenylketonuria Treatment Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Route of Administration

6.3.5.2.2.           By Product

6.3.5.2.3.           By Distribution Channel

7.    Europe Phenylketonuria Treatment Market Outlook

7.1.  Market Size & Forecast

7.1.1.        By Value

7.2.  Market Share & Forecast

7.2.1.        By Route of Administration

7.2.2.        By Product

7.2.3.        By Distribution Channel

7.2.4.        By Country

7.3.  Europe: Country Analysis

7.3.1.        France Phenylketonuria Treatment Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Route of Administration

7.3.1.2.2.           By Product

7.3.1.2.3.           By Distribution Channel

7.3.2.        Germany Phenylketonuria Treatment Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Route of Administration

7.3.2.2.2.           By Product

7.3.2.2.3.           By Distribution Channel

7.3.3.        Spain Phenylketonuria Treatment Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Route of Administration

7.3.3.2.2.           By Product

7.3.3.2.3.           By Distribution Channel

7.3.4.        Italy Phenylketonuria Treatment Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Route of Administration

7.3.4.2.2.           By Product

7.3.4.2.3.           By Distribution Channel

7.3.5.        United Kingdom Phenylketonuria Treatment Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Route of Administration

7.3.5.2.2.           By Product

7.3.5.2.3.           By Distribution Channel

8.    North America Phenylketonuria Treatment Market Outlook

8.1.  Market Size & Forecast

8.1.1.        By Value

8.2.  Market Share & Forecast

8.2.1.        By Route of Administration

8.2.2.        By Product

8.2.3.        By Distribution Channel

8.2.4.        By Country

8.3.  North America: Country Analysis

8.3.1.        United States Phenylketonuria Treatment Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Route of Administration

8.3.1.2.2.           By Product

8.3.1.2.3.           By Distribution Channel

8.3.2.        Mexico Phenylketonuria Treatment Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Route of Administration

8.3.2.2.2.           By Product

8.3.2.2.3.           By Distribution Channel

8.3.3.        Canada Phenylketonuria Treatment Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Route of Administration

8.3.3.2.2.           By Product

8.3.3.2.3.           By Distribution Channel

9.    South America Phenylketonuria Treatment Market Outlook

9.1.  Market Size & Forecast

9.1.1.        By Value

9.2.  Market Share & Forecast

9.2.1.        By Route of Administration

9.2.2.        By Product

9.2.3.        By Distribution Channel

9.2.4.        By Country

9.3.  South America: Country Analysis

9.3.1.        Brazil Phenylketonuria Treatment Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Route of Administration

9.3.1.2.2.           By Product

9.3.1.2.3.           By Distribution Channel

9.3.2.        Argentina Phenylketonuria Treatment Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Route of Administration

9.3.2.2.2.           By Product

9.3.2.2.3.           By Distribution Channel

9.3.3.        Colombia Phenylketonuria Treatment Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Route of Administration

9.3.3.2.2.           By Product

9.3.3.2.3.           By Distribution Channel

10. Middle East and Africa Phenylketonuria Treatment Market Outlook

10.1.             Market Size & Forecast

10.1.1.     By Value

10.2.             Market Share & Forecast

10.2.1.     By Route of Administration

10.2.2.     By Product

10.2.3.     By Distribution Channel

10.2.4.     By Country

10.3.             MEA: Country Analysis

10.3.1.     South Africa Phenylketonuria Treatment Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Route of Administration

10.3.1.2.2.         By Product

10.3.1.2.3.         By Distribution Channel

10.3.2.     Saudi Arabia Phenylketonuria Treatment Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Route of Administration

10.3.2.2.2.         By Product

10.3.2.2.3.         By Distribution Channel

10.3.3.     UAE Phenylketonuria Treatment Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Route of Administration

10.3.3.2.2.         By Product

10.3.3.2.3.         By Distribution Channel

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global Phenylketonuria Treatment Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   BioMarin Pharmaceutical Inc.

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   Synlogic, Inc.

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   Retrophin, Inc.

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   Daiichi Sankyo Company, Limited

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   Codexis, Inc.

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   SOM Innovation Biotech SL

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   Homology Medicines, Inc.

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Phenylketonuria Treatment Market was estimated to be USD 502.18 million in 2022.

down-arrow

Codexis, Inc., Daiichi Sankyo Company Limited are some of the key players operating in the Phenylketonuria Treatment Market.

down-arrow

Developing more effective and accessible treatment options remains a challenge.

down-arrow

Gene therapy research in the treatment of PKU was gaining momentum.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Phenylketonuria Treatment Market to grow with a CAGR of 11.20%

Oct, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Phenylketonuria Treatment Market.

Why Choose Us